Gene and Molecular Therapies in Neurogenetics
5 sections · 25 min
Categories of Gene and Molecular Therapy
Gene and molecular therapies for neurological disorders span a spectrum from gene replacement (delivering a functional copy of the deficient gene) to gene silencing (reducing production of a toxic gain-of-function protein) to gene editing (correcting a specific pathogenic variant in situ). Each approach has distinct mechanisms, delivery challenges, and appropriate applications depending on whether the disorder results from loss-of-function or gain-of-function pathogenic mechanisms.
Key Points
- Gene addition/replacement: deliver functional gene copy via viral vector (AAV) or non-viral carrier; appropriate for recessive loss-of-function disorders; does not alter genomic DNA — the transgene remains episomal in neurons; examples: SMA (Zolgensma), Fabry (Phase 3), hemophilia
- Gene silencing — antisense oligonucleotides (ASOs): short (18–25 nt) chemically modified single-stranded DNA oligomers that bind target mRNA via Watson-Crick base pairing → RNaseH-mediated mRNA degradation or steric blockade of translation/splicing; intrathecal or IV delivery; examples: nusinersen (SMA), tofersen (SOD1-ALS), inotersen (hATTR)
- Gene silencing — RNA interference (RNAi): siRNA or shRNA; double-stranded RNA triggers RISC complex to cleave complementary mRNA; examples: inclisiran (PCSK9-targeting siRNA — subcutaneous), patisiran (TTR-siRNA for hATTR — IV lipid nanoparticle)
- Gene editing — CRISPR-Cas9: guided by sgRNA; creates double-strand break at specific genomic locus; HDR corrects sequence (in dividing cells) or NHEJ creates indels (in post-mitotic neurons — limited HDR); base editors and prime editors avoid DSBs; Casgevy (sickle cell/beta-thal) — first approved CRISPR therapy (2023)
- mRNA therapeutics: delivery of modified mRNA encoding the therapeutic protein; transient expression without genomic integration; lipid nanoparticle delivery; relevant to IEM (OTC deficiency trials), neurological applications emerging
✦ Check Your Understanding
Which statement correctly distinguishes gene addition therapy from gene editing for neurological disorders?
Select an answer to reveal the explanation
AAV Vector Biology and CNS Delivery
Adeno-associated virus (AAV) is the dominant vector for in vivo gene therapy in neurology. AAV is a small (25 nm), non-enveloped, single-stranded DNA virus that is naturally replication-deficient. Recombinant AAV (rAAV) retains only the inverted terminal repeats (ITRs) flanking the therapeutic transgene — all viral coding sequences are removed, reducing immunogenicity. Serotype selection (AAV1, 2, 5, 8, 9, AAVrh10, etc.) determines cell tropism, tissue distribution, and CNS penetration.
Key Points
- AAV9 and AAVrh10: preferred serotypes for CNS gene therapy; cross the blood-brain barrier after intravenous administration (most efficiently in neonates/young children — BBB permeability decreases with age); transduce both neurons and astrocytes; used in SMA (Zolgensma), Batten disease, MLD trials
- Cargo capacity: maximum ~4.7 kb insert — limits use for very large genes (DMD full-length cDNA = 14 kb, too large; micro-dystrophin constructs used instead); suitable for SMN1 (1.7 kb), MECP2 (1.5 kb), ARSA (MLD), CLN genes (Batten)
- Episomal persistence: rAAV DNA remains largely episomal (non-integrating) in post-mitotic neurons — gene expression is stable long-term without insertional mutagenesis risk; in rapidly dividing cells, expression is lost with each division
- Routes of administration for CNS: IV (crosses BBB in young patients, requires high dose); intrathecal/intracerebroventricular (reduces dose needed, bypasses BBB, spreads via CSF); direct intraparenchymal (focal delivery — Parkinson's, Alzheimer's trials); intravitreal (eye diseases — LCA/RPE65)
- Immune responses: pre-existing anti-AAV neutralizing antibodies (from natural AAV infection) — prevalent in adults (40–70% positive for AAV9 NAb); NAb seropositivity may exclude patients from IV gene therapy trials; complement activation (CARPA — complement-mediated pseudo-allergic reaction) is a risk with high-dose IV AAV; immunosuppression protocols essential
✦ Check Your Understanding
Why is the cargo capacity of AAV vectors (~4.7 kb) a significant challenge for DMD gene therapy?
Select an answer to reveal the explanation
Approved Neurological Gene Therapies
The past decade has seen the approval of several transformative gene therapy products for neurological diseases, representing the first treatments that address the underlying genetic defect rather than managing symptoms. Each approval has provided important lessons about vector biology, immune management, patient selection, and long-term durability.
Key Points
- Onasemnogene abeparvovec (Zolgensma, AveXis/Novartis): AAV9-SMN1; single IV infusion; approved FDA 2019 for SMA in patients <2 years; >30,000 USD/year → 2.1 million USD one-time dose; presymptomatic treatment near-normalizes motor outcomes; dorsal root ganglion toxicity seen in primate studies at high doses — clinical monitoring required; see the [[neuromuscular|Genetic Neuromuscular Disorders]] module for detailed SMA coverage including SMN2 copy number correlation and all approved therapies
- Voretigene neparvovec (Luxturna, Spark): AAV2-RPE65; subretinal injection; approved FDA 2017 for RPE65-related Leber congenital amaurosis; bilateral treatment; sustained visual improvement; 425,000 USD per eye — first approved in vivo AAV gene therapy in the US
- Delandistrogene moxeparvovec (Elevidys, Sarepta): AAVrh74-micro-dystrophin; IV infusion; approved FDA 2023 (accelerated) for DMD ages 4–5 years; uses engineered micro-dystrophin (functional mini-protein, 138 kDa); ongoing trials in older patients
- Atidarsagene autotemcel (Libmeldy, Orchard): ex vivo autologous HSC transduction with lentiviral ARSA; approved EMA 2020 for metachromatic leukodystrophy in pre-symptomatic or early symptomatic patients; longest follow-up >10 years; no neurological progression vs. natural history
- Betibeglogene autotemcel (Zynteglo) and elivaldogene autotemcel (Skysona): ex vivo HSC gene therapy for beta-thalassemia and cerebral adrenoleukodystrophy respectively — establish lentiviral HSC platform for CNS demyelinating leukodystrophies
✦ Check Your Understanding
An 8-month-old boy is diagnosed with SMA type 1 (SMN1 homozygous deletion, SMN2 copy number 2). He has progressive respiratory insufficiency. His parents ask whether gene therapy (onasemnogene abeparvovec/Zolgensma) is appropriate. Which factor most limits his eligibility?
Select an answer to reveal the explanation
Antisense Oligonucleotide Therapies
Antisense oligonucleotides (ASOs) are synthetic oligonucleotides (18–25 nucleotides) designed to bind specific RNA sequences via complementary base pairing, modulating RNA fate by multiple mechanisms. Chemical modifications (phosphorothioate backbone, 2'-O-methyl, LNA, PMO) protect ASOs from nuclease degradation and improve target affinity. ASOs administered intrathecally distribute broadly throughout the CSF compartment and penetrate neurons and glia, providing effective CNS delivery without viral vectors.
Key Points
- Nusinersen (Spinraza, Biogen): intrathecal ASO; targets ISS-N1 element in SMN2 intron 7, blocking hnRNP binding and forcing exon 7 inclusion → increased full-length SMN2 mRNA; approved 2016; loading doses then q4 months maintenance; transformative in infantile-onset SMA; ENDEAR and CHERISH trials
- Tofersen (Qalsody, Biogen): intrathecal ASO; targets SOD1 mRNA; RNaseH-mediated cleavage reduces SOD1 protein; approved FDA 2023 for SOD1-ALS; first approved treatment specifically for a monogenic subtype of ALS; reduces CSF/plasma NFL (neurofilament light) biomarker
- Inotersen and eplontersen: RNaseH ASO targeting TTR mRNA (both mutant and wild-type); reduce TTR production; subcutaneous injection; approved for hereditary transthyretin amyloid polyneuropathy (hATTR-PN); patisiran (siRNA) has similar mechanism and indication
- UBE3A-ATS ASO for Angelman syndrome: targets the non-coding antisense transcript that silences paternal UBE3A in neurons; Phase 1/2 trials show paternal UBE3A protein restoration; toxicity in primates caused temporary pause — development ongoing with modified dosing regimen
✦ Check Your Understanding
An infant with SMA type 1 (homozygous SMN1 deletion, SMN2 copy number = 2) is treated with nusinersen. The drug increases full-length SMN protein. Why does this approach target SMN2 rather than correcting SMN1?
Select an answer to reveal the explanation
Practical Considerations, Challenges, and Future Directions
The clinical implementation of gene therapies requires addressing formidable practical challenges: patient selection (age, weight, immune status, antibody titers), cost and access, monitoring for immune adverse events, long-term durability of expression, and re-dosing limitations. The field is rapidly advancing with new targets, improved vectors, and evolving regulatory frameworks.
Key Points
- Pre-existing AAV neutralizing antibodies: AAV9 NAb ≥1:50 typically excludes patients from IV gene therapy — antibodies block transduction; prevalence increases with age; patients can be screened and enrolled when NAb titers decline naturally; plasmapheresis to reduce NAb titers is experimental
- Immunosuppression protocols: prednisolone 1 mg/kg/day initiated before and continued weeks after AAV administration to suppress T-cell response to viral capsid; anti-CD20 (rituximab) added in high-risk protocols; liver enzyme monitoring for AAV hepatotoxicity
- Episomal dilution in growing livers: in infants, rapidly dividing hepatocytes dilute episomal rAAV → decreasing expression over years; this is a critical limitation for early-treated SMA patients approaching adolescence — combination with ASO (nusinersen) may address durability
- Re-dosing challenges: once immune response to AAV capsid develops after first dose, subsequent doses of the same serotype are inefficient; cross-reactive immunity between serotypes complicates switching; next-generation capsid engineering (machine learning-designed capsids, deimmunized capsids) aims to address this
- Emerging neurological gene therapy targets: Huntington disease (HTT lowering ASO/siRNA/CRISPR — clinical trials underway), Parkinson disease (AADC, GAD1/2 — symptom modification), Alzheimer disease (APOE4 gene editing), Batten disease/NCL (CLN2 AAV — cerliponase alfa approved intrathecal for CLN2), Rett syndrome (MECP2 AAV — dose-sensitive), GM1/GM2 gangliosidosis (multiple programs). Note: Lecanemab (Leqembi) is an anti-amyloid-beta monoclonal antibody (NOT an ASO or gene therapy) — FDA approved 2023 for early Alzheimer's disease. Mechanism: binds soluble Abeta protofibrils for clearance. ARIA (amyloid-related imaging abnormalities) is the key safety concern; APOE4 homozygotes have highest ARIA risk
✦ Check Your Understanding
A patient with SOD1-ALS is started on tofersen. Six months later, plasma neurofilament light (NfL) chain drops substantially. This biomarker change most directly indicates:
Select an answer to reveal the explanation
0 of 5 sections read
Scroll through all sections to track your progress.